FDA announced the availability of a draft guidance for industry, “Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues.”
With major leadership changes, grant disruptions and terminations, and a stoked distrust in science, Steven Artandi, the director of Stanford Cancer Center, worries that young investigators will feel disenchanted by the U.S. research atmosphere and take their work and study elsewhere.
